Commercial Incubators at TRI

Our TRI incubator space houses start-ups or early stage companies that demonstrate the pipeline for innovation to product and are important partners in the translational model.

This model bridges a current gap in the market by providing the initial laboratory space needed for small to medium biotech/medtech companies.

The TRI facility gives them time to establish, test and develop their products and provides an environment with access to leading core facilities and access to researchers, patients and clinical trial facilities.

The space includes offices, wet labs, clean rooms, cold storage, equipment rooms; and access to specialist technologies and expertise in TRI’s Core and Clinical Research and Clinical Trials Facilities.

The companies selected to work in the TRI building:

  • commercialise medical innovations
  • offer training and specialist services
  • transfer knowledge
  • partner to change culture and bring industry and research closer together

Our current companies based at TRI are:

TRI Incubator Companies

Admedus Immunotherapies

Admedus is a global medical technologies company that delivers clinically superior solutions to help healthcare professionals create life-changing outcomes for patients worldwide.

Former from a merger of Allied Healthcare Group Ltd and bioMD Ltd, is a unique healthcare company with assets in research and development, products in advanced clinical trials ready for commercialisation, and a successful sales, marketing and medical device distribution business.

Admedus’s ADAPT® products have achieved nine years without calcification or degradation and their products are currently being used in more than 135 global centres in Australia, Europe, US, Canada, Singapore, Malaysia, India, Hong Kong and the Middle East.

Admedus has initiated and completed a Phase I/IIa clinical trial in HSV-2 infected patients to evaluate the safety, tolerability and immunogenicity of the therapeutic HSV-2 DNA vaccine developed by Professor Ian Frazer.

Admedus commenced Phase I clinical trial in 2018 to test a therapeutic vaccine in HPV+ head and neck cancer patients at the PA Hospital. The trial is being run by Co-investigators Professors Frazer and Porceddu at the TRI Clinical Research Facility.  This trial is funded in part by Advance Queensland and the Queensland Head and Neck Cancer Centre.


Vaxxas is focussed on enhancing performance of existing and next generation vaccines through development and commercialisation of the company's novel vaccine delivery technology - the Nanopatch™

It’s a venture capital funded technology start-up company developing a technology that originated from research at The University of Queensland.

Vaxxas utilises the TRI Core Facilities to develop the pipeline products through pre-clinical development to final clinical manufacture using GMP cleanrooms located in the commercial space Floor 3

Vaxxas provided grant of $60,000 to develop an in-vitro release assay for their microinjection technology with TRI

In 2017 TRI and Vaxxas received MTP Connect grant of $500k for Australian-first manufacturing and hands-on training facility, Australian-first manufacturing and hands-on training facility to produce medical products for early stage human clinical trials

Since relocating to the TRI in 2015, Vaxxas has rapidly translated from a small university-based entity to a medium sized biotech company with over 30 staff.  Utilising the available space at the TRI including office, laboratory and cleanrooms, Vaxxas is nearing completion of its third clinical trial.

Vaxxas has established a pipeline of products with collaboration with some of the biggest vaccine manufacturers and humanitarian organisations in the world. Vaxxas utilises the core facilities at the TRI to develop the pipeline products through pre-clinical development to final clinical manufacture using the GMP cleanrooms located in the commercial space.

Vale Life Sciences

Vale Life Sciences began at TRI in July 2017. 

Vale’s patented products, which have been designed by researchers, improve the reproducibility and relevance of biological experiments.  They provide new, cost-effective solutions to known problems encountered in the research field.

The company’s first new technology, Happy Cell ASM is a novel, multi-purpose cell culture reagent, used primarily for the 3D cell culture market. It has been trialled by researchers in the TRI and has formed part of specific research in areas such as prostate, lung and head and neck cancers and has provided valuable findings.  A number of research publications have been written as a result. Happy Cell ASM is now available commercially and is being supplied to research institutions and universities in Australia and overseas.

The positive results achieved through the use of Happy Cell ASM have resulted in further R & D, with additional uses identified.  We are continuing to work collaboratively with other stakeholders in the TRI as we research uses and applications for this product.

Vale has also developed specially designed microplates and is in the process of perfecting these products.  This special microplate system substantially lowers the costs of cell and tissue-based research and has the potential to reduce the costs of experimentation by up to 1000 times.

Ocugene/Layton Vision Foundation

Ocugene is a biotechnology company based at the TRI and founded by prominent Brisbane Ophthalmologist,
A/Prof Chris Layton and former National Institutes of Health (NIH) Molecular Biologist, Jason Steel. 

Ocugene develops next generation retinal therapeutics and gene delivery vectors with enhanced safety profiles for diseases such as macular degeneration, uveitis and uveal melanoma.  Ocugene's core products are enhanced gene therapy vectors with proven activity in models of ocular angiogenic, inflammatory and neoplastic diseases.  Ocugene's vectors are designed to be regulatable, allowing clinicians to tailor delivery of therapeutics based on the severity of each patients’ condition.   

In partnership with the Layton Vision Foundation, Ocugene funds research fellowships and not for profit ophthalmic research.

2018, its officers provided supervision and financial support for six higher research degree students at three universities.  In addition, its associates, based at TRI, funded and set up a charitable diabetic retinopathy screening service in Port Vila, Vanuatu.


Microba uses DNA to analyse gut microbes to help develop diagnostics and targeted biotherapeutic remedies for diseases such as inflammatory bowel disease, colon cancer, diabetes and depression.

Metagenomic sequencing, developed by Microba's co-founders, microbiologists Phil Hugenholtz and Professor Gene Tyson, is the most advanced DNA sequencing method available. It is more accurate and comprehensive than existing methods of DNA testing for gut bacteria or longstanding approaches such as testing live cultures. 

Biotherapeutics are live bacteria that mimic the functions of a healthy gut "microbiome". Customised cocktails of these bacteria that can be ingested and engrafted onto the large intestine's mucosal lining to bolster the immune and metabolic systems to treat a range of diseases. 

Microba has built a state-of-the-art laboratory at TRI using the latest sequencing and robotic technology.  They have now processed over 2,500 samples and are partnering with numerous research groups.


Dendright is a Uniquest spin-off company founded to commercialise the product, DEN-181, in partnership with Janssen-Biotech.

Prof Ranjeny Thomas, UQDI, developed the immunotherapy product to target Rheumatoid Arthritis. 

In 2017, Dendright began a Phase 1 clinical trial with Rheumatoid Arthritis patients overseen by Dr Phillip Vecchio, Princess Alexandra Hospital, at the TRI Clinical Research Facility.

Laboratory work for Dendright uses TRI Core Facilities in imaging, microscopy, histology and flow cytometry.


CARP is a new business model developing new therapeutics and technologies for treatment of cancer and age related disorders.  The CARP team has identified proteins that are linked to both cancer and ageing. Their research team initially identified a key DNA repair protein and it is thought to function in the detection and repair of DNA damage and is essential for cellular viability.

The company includes a mathematician, a mechatronics engineer, a preclinical studies team, a drug development team, a discovery team and a structural biology team.

The first drug licensed to the spin out company CARP Pharmaceuticals, have committed $7m to further development of the drug DKLS02 towards patients and is currently in toxicology studies and is planned to enter Phase I trials in 2019.

CARP has external industry partners including biomarker development with Hirotsu Bio Sciences and assay development with Sticky Cell